Our Treatment

Engineering Plasma Physics
to Fight Cancer…

Our research team (JCRI-ABTS) at US Medical Innovations is using
Cold Atmospheric Plasma to selectively Target Cancer Cells and
Disrupt the Cell’s ability to Reproduce and Survive.1

What is Canady HeliosTM Cold Plasma?

Canady Helios Cold Plasma (CHCP) is a non-thermal process that according to JCRI/ABTS Research, triggers chemical-molecular changes in cancer cells leading to apoptosis (cell death), while normal cells are left unharmed.

The Cold Plasma Beam introduces electronically charged particles, Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS) to the Plasma Treatment Electrical Field (PTEF).1

A Multi-Disciplinary Treatment Process

A Typical Treatment Process

1. Pre-Operative Phase:
Patient Diagnosed with Soild Tumor

2. Pre-Operative Phase:
Standard Treatment Protocol - Radiation and/or Chemotherapy

3A - Intra-Operative Phase:
Removal of Tumor

3B - Intra-Operative Phase:
Application of Canady Helios Cold Plasma

4. Post-Operative Follow-up:
Chemotherapy / Radiotherapy
(depending on the multi-disciplinary team)

Safe – No Side Effects

The pioneering JCRI/ABTS Research proves when used intraoperatively (during your surgery), this low-temperature plasma treatment selectively targets cancer cells without damaging healthy surrounding tissue.1

There is no hair loss or other side effects.

CHCP may be very effective
in treating Solid Tumor Cancers

Based on JCRI/ABTS Research, spraying CHCP in the surgical margins during your cancer surgery may reduce the chance of local recurrence and may improve your chance of survival.1-7

1. The First Cold Atmospheric Plasma Phase I Clinical Trial for the Treatment of Advanced Solid Tumors: A Novel Treatment Arm for Cancer
Cancers 2023, 15(14), 3688; – https://doi.org/10.3390/cancers15143688

2. Canady Cold Helios Plasma Reduces Soft Tissue Sarcoma Viability by Inhibiting Proliferation, Disrupting Cell Cycle, and Inducing Apoptosis: A Preliminary Report
Molecules 2022, 27(13), 4168; – https://doi.org/10.3390/molecules27134168

3. The Granger Causal Effects of Canady Helios Cold Plasma on the Inhibition of Breast Cancer Cell Proliferation
Appl. Sci. 2022, 12(9), 4622; https://doi.org/10.3390/app12094622

4. BCL2A1 Regulates Canady Helios Cold Plasma-induced Cell Death in Triple-Negative Breast Cancer
Scientific Reports volume 12, Article number: 4038 (2022) – https://www.nature.com/articles/s41598-022-07027-4

5. Canady Helios Cold Plasma Induces Breast Cancer Cell Death by Oxidation of Histone mRNA
Int. J. Mol. Sci. 2021, 22(17), 9578; – https://doi.org/10.3390/ijms22179578

6. The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro
Scientific Reports volume 11, Article number: 8967 (2021) – https://www.nature.com/articles/s41598-021-88451

7. Canady cold plasma conversion system treatment: An effective inhibitor of cell viability in breast cancer molecular subtypes
Clinical Plasma Medicine (Elsevier) Volumes 19–20, September–December 2020, 100109. – https://doi.org/10.1016/j.cpme.2020.100109

THE SCIENCE OF COLD PLASMA

Canady Helios Cold Plasma Induces Non-Thermal (24 °C), Non-Contact Irreversible Electroporation and Selective Tumor Cell Death at Surgical Margins

Published: 2 December 2025 Saravana R. K. Murthy, Taisen Zhuang, Olivia Z. Jones, Yasmine Dakak, Michael Keidar, Aviram Nissan, and Jerome Canady. Residual tumor cells left behind after surgery are a major cause of cancer local recurrence. The Canady Helios Cold...

Canady Helios Cold Plasma Induces Non-Thermal (24 °C), Non-Contact Irreversible Electroporation and Selective Tumor Cell Death at Surgical Margins

Saravana R. K. Murthy, Taisen Zhuang, Olivia Z. Jones, Yasmine Dakak, Michael Keidar, Aviram Nissan, and Jerome Canady. Residual tumor cells left behind after surgery are a major cause of cancer local recurrence. The Canady Helios Cold Plasma (CHCP) system is a...

The First Cold Atmospheric Plasma Phase I Clinical Trial for the Treatment of Advanced Solid Tumors: A Novel Treatment Arm for Cancer

Jerome Canady, Saravana R. K. Murthy, Taisen Zhuang, Steven Gitelis, Aviram Nissan, Lawan Ly, Olivia Z. Jones, Xiaoqian Cheng, Mohammad Adileh, Alan T. Blank, Matthew W. Colman, Kieth Millikan, Cristina O’Donoghue, Kerstin M. Stenson, Karen Ohara, Gal Schtrechman,...

Canady Cold Helios Plasma Reduces Soft Tissue Sarcoma Viability by Inhibiting Proliferation, Disrupting Cell Cycle, and Inducing Apoptosis: A Preliminary Report

Lawan Ly, Xiaoqian Cheng, Saravana R. K. Murthy, Olivia Z. Jones, Taisen Zhuang, Steven Gitelis, Alan T. Blank, Aviram Nissan, Mohammad Adileh, Matthew Colman, Michael Keidar, Giacomo Basadonna and Jerome Canady Soft tissue sarcomas (STS) are a rare and highly...

The Granger Causal Effects of Canady Helios Cold Plasma on the Inhibition of Breast Cancer Cell Proliferation

Annisa Elbedour, Xiaoqian Cheng, Saravana R. K. Murthy, Taisen Zhuang, Lawan Ly, Olivia Jones, Giacomo Basadonna, Michael Keidar, and Jerome CanadyCold atmospheric plasma (CAP) has become a promising tool for modern medicine. With its recent applications in oncology,...